Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 20/20 | 0.71 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20513563 | 1.00 | CYP11B2 (0.71) | CYP11B2CYP11B1 | |
| SCHEMBL18489953 | 0.83 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL18489952 | 0.83 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL22236835 | 0.82 | CYP11B2 (0.74) | CYP11B2 | |
| SCHEMBL18791093 | 0.79 | CYP11B2 (0.66) | CYP11B2CYP11B1 | |
| SCHEMBL18791027 | 0.78 | CYP11B2 (0.48) | CYP11B2CYP11B1 | |
| SCHEMBL18791032 | 0.77 | CYP11B2 (0.48) | CYP11B2CYP11B1 | |
| SCHEMBL18791026 | 0.76 | GAA (0.53) | CYP11B2CYP11B1 | |
| SCHEMBL20547130 | 0.76 | CYP11B2 (0.43) | CYP11B2CYP11B1 | |
| SCHEMBL18489909 | 0.74 | CYP11B2 (1.00) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-07-21 | — | — | US | claimed |
| EP-3381904-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-10-03 | — | — | EP | claimed |
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-07-21 | — | — | US | disclosed |
| US-20180312503-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-01 | — | — | US | disclosed |
| EP-3381904-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | REN, NR3C2, NR5A1 | CYP11B2 8/4885CYP11B1 6/4885 |
| US-20180312503-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | REN, NR3C2, NR5A1 | CYP11B2 8/4885CYP11B1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.